Table 1 Baseline patient and disease characteristics.
Characteristic | Monotherapy (n = 14) | Combination therapy (n = 16) |
|---|---|---|
Median age, years (range) | 60 (49–70) | 61 (30–78) |
Sex, n (%) | ||
Female | 9 (64.3) | 5 (31.3) |
Male | 5 (35.7) | 11 (68.8) |
Race, n (%) | ||
Black or African American | 0 | 1 (6.3) |
White | 11 (78.6) | 14 (87.5) |
Other | 3 (21.4) | 1 (6.3) |
Ethnicity, n (%) | ||
Hispanic or Latino | 2 (14.3) | 0 |
Not Hispanic or Latino | 12 (85.7) | 16 (100) |
ECOG PS, n (%) | ||
0 | 5 (35.7) | 5 (31.3) |
1 | 9 (64.3) | 10 (62.5) |
Missing | 0 | 1 (6.3) |
Primary tumour location, n (%) | ||
Endometrial | 0 | 2 (12.5) |
Liver | 2 (14.3) | 0 |
Lung | 0 | 5 (31.3) |
Ovary | 2 (14.3) | 1 (6.3) |
Pancreas | 2 (14.3) | 0 |
Uterus | 0 | 3 (18.8) |
Other† | 8 (57.1) | 5 (31.3) |
Overall disease classification, n (%) | ||
Metastatic | 10 (71.4) | 12 (75.0) |
Locally advanced | 1 (7.1) | 1 (6.3) |
Both | 3 (21.4) | 3 (18.8) |
Type of prior systemic therapy, n (%) | ||
Cytotoxic chemotherapy | 6 (42.9) | 11 (68.9) |
Hormonal therapy | 1 (7.1) | 1 (6.3) |
Immunotherapy | 8 (57.1) | 5 (31.3) |
Targeted therapy | 4 (28.6) | 6 (37.5) |
Other†† | 3 (21.4) | 2 (12.5) |
Median number of prior systemic therapies, n (range) | 4 (1–10) | 2 (1–10) |
